Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
This study will evaluate efficacy and safety of Toripalimab Injection (JS001) with or without Lenvatinib as a Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
DRUG: Toripalimab (JS001 )|DRUG: Toripalimab (JS001 ) Lenvatinib|DRUG: Toripalimab (JS001 ) Lenvatinib
Pathological response rate, CPRï¼ŒMPR, Up to 2 months
Objective response rate, ORR is defined as the percentage of participants who achieved CR or PR, up to 2 months|Percentage of R0 resection, Used for assessment of the feasibility of the neoadjuvant therapy., up to 8 months|Time to operation, Used for assessment of the feasibility of the neoadjuvant therapy., up to 8 months|Progression free survival, Used for assessment of the efficacy., up to 3 years|Overall survival, Used for assessment of the efficacy., up to 3 years|Incidence of adverse events, Graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Safety will be recorded through the incidence of adverse events, serious adverse events and specific laboratory abnormalities (worst grade) in each treatment arm., up to 3 years
This study will evaluate efficacy and safety of Toripalimab Injection (JS001) with or without Lenvatinib as a Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma (HCC)